Alyeska Investment Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Alyeska Investment Group’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,709	Closed	-$922K	–	513
2019 Q3	$922K	Buy	7,709 +6,575	+580%	+$1.32M	0.01%	328
2019 Q2	$339K	Sell	1,134 -1,585	-58%	-$661K	﹤0.01%	416
2019 Q1	$1.22M	Buy	2,719 +8	+0.3%	+$3.5K	0.02%	307
2018 Q4	$1.24M	Buy	+2,711	New	+$1.68M	0.02%	310
2018 Q3	–	Sell	-1,667	Closed	-$978K	–	543
2018 Q2	$978K	Buy	+1,667	New	+$1.09M	0.01%	399
2016 Q1	–	Sell	-498	Closed	-$391K	–	473
2015 Q4	$391K	Sell	498 -136	-21%	-$134K	﹤0.01%	360
2015 Q3	$870K	Buy	634 +58	+10%	+$89.6K	0.01%	398
2015 Q2	$1.16M	Buy	+576	New	+$1.47M	0.01%	397

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Alyeska Investment Group's HTGM Position: Q4 2019 in Review

Alyeska Investment Group sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 7,709 shares — an estimated $922K sold.

Alyeska Investment Group first reported a position in HTGM in Q2 2015 and held it in 8 quarters. The position peaked at $1.24M in Q4 2018. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

Alyeska Investment Group reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Alyeska Investment Group sold 7,709 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $922K.
Alyeska Investment Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 8 quarters.
Alyeska Investment Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.24M in Q4 2018.
27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Alyeska Investment Group's 13F filing for Q4 2019, filed 14 Feb 2020.